Advertisement
Research Article| Volume 43, ISSUE 12, P2308-2314, December 2017

Download started.

Ok

Correlation of clinicopathologic features and lung squamous cell carcinoma subtypes according to the 2015 WHO classification

  • Rongrong Chen
    Affiliations
    Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
    Search for articles by this author
  • Zhengping Ding
    Affiliations
    Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
    Search for articles by this author
  • Lei Zhu
    Affiliations
    Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
    Search for articles by this author
  • Shun Lu
    Correspondence
    Corresponding author. Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 West Huaihai Road, Xuhui District, Shanghai 200030, China.
    Affiliations
    Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
    Search for articles by this author
  • Yongfeng Yu
    Correspondence
    Corresponding author. Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 West Huaihai Road, Xuhui District, Shanghai 200030, China.
    Affiliations
    Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China
    Search for articles by this author
Published:September 18, 2017DOI:https://doi.org/10.1016/j.ejso.2017.09.011

      Abstract

      Aims

      This study aimed to determine the relationship between clinicopathologic features and lung squamous cell carcinoma (LSCC) subtypes according to the 2015 WHO classification.

      Methods

      We identified 824 operable LSCC patients undergoing a complete surgical resection at Shanghai Chest Hospital between April 2015 and January 2017. Immunohistochemistry was used to investigate the clinicopathologic features.

      Results

      Among them, the percentages of LSCC subtypes were 66.1% (545/824), 28.6% (236/824), and 5.2% (43/824) for keratinizing squamous cell carcinoma (KSCC), nonkeratinizing squamous cell carcinoma (NKSCC), and basaloid squamous cell carcinoma (BSCC), respectively. There were more males, more smokers, and more pneumonectomy surgeries in KSCC patients (p = 0.008, p = 0.000, p = 0.043). There were more N2 lymph node involvement and pathological stage III in NKSCC patients (p = 0.01, p = 0.03). BSCC did not demonstrate specificity to anything, but expressed adenocarcinoma markers more frequently. No significant difference existed between pathological subtypes and other clinicopathologic features, such as age, location type, visceral pleural involvement and lymphovascular invasion. The frequencies of EGFR sensitive mutations and ALK rearrangements were not significantly different among three subtypes.

      Conclusion

      Significant relationships exist between some clinicopathologic features and LSCC subtypes.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.
        • Ma J.
        • Zou Z.
        • Jemal A.
        Cancer statistics.
        CA Cancer J Clin. 2014; 64: 9-29
        • Youlden D.R.
        • Cramb S.M.
        • Baade P.D.
        The international epidemiology of lung cancer: geographical distribution and secular trends.
        J Thorac Oncol. 2008; 3: 819-831
        • Travis W.D.
        • Brambilla E.
        • Noguchi M.
        • Nicholson A.G.
        • Geisinger K.R.
        • Yatabe Y.
        • et al.
        International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma.
        J Thorac Oncol. 2011; 6: 244-285
        • Oliver T.G.
        • Patel J.
        • Akerley W.
        Squamous non-small cell lung cancer as a distinct clinical entity.
        Am J Clin Oncol. 2015; 38: 220-226
        • Cetin K.
        • Ettinger D.S.
        • Hei Y.J.
        • O'Malley C.D.
        Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the surveillance, epidemiology and end results program.
        Clin Epidemiol. 2011; 3: 139-148
        • Gressett S.M.
        • Shah S.R.
        Intricacies of bevacizumab-induced toxicities and their management.
        Oncology. 2009; 43: 490-501
        • Johnson D.H.
        • Fehrenbacher L.
        • Novotny W.F.
        • Herbst R.S.
        • Nemunaitis J.J.
        • Jablons D.M.
        • et al.
        Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
        J Clin Oncol. 2004; 22: 2184-2191
        • Selvaggi G.
        • Scagliotti G.V.
        Histologic subtype in NSCLC: does it matter?.
        Oncology. 2009; 23: 1133-1140
        • Scagliotti G.V.
        • Parikh P.
        • von Pawel J.
        • Biesma B.
        • Vansteenkiste J.
        • Manegold C.
        • et al.
        Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
        J Clin Oncol. 2008; 26: 3543-3551
        • Travis W.D.
        • Brambilla E.
        • Nicholson A.G.
        • Yatabe Y.
        • Austin J.H.M.
        • Beasley M.B.
        • et al.
        The 2015 World Health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification.
        J Thorac Oncol. 2015; 10: 1243-1260
        • Beasley M.B.
        • Brambilla E.
        • Travis W.D.
        The 2004 world health organization classification of lung tumors.
        Semin Roentgenol. 2005; 40: 90-97
        • Rami-Porta R.
        • Wittekind C.
        • Goldstraw P.
        • International Association for the Study of Lung Cancer (IASLC) Staging Committee
        Complete resection in lung cancer surgery: proposed definition.
        Lung Cancer. 2005; 49: 25-33
        • Ludwig M.S.
        • Goodman M.
        • Miller D.L.
        • Johnstone P.A.
        Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer.
        Chest. 2005; 128: 1545-1550
        • Hammar S.P.
        Common neoplasms.
        in: Dail D.H. Hammar S.P. Pulmonary pathology. Springer Verlag, New York, NY1994: 1123-1278
        • Zhang Q.
        • Zhu L.
        • Zhang J.
        Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese patients.
        BMC Cancer. 2015; 15: 88
        • Park S.K.
        • Cho L.Y.
        • Yang J.J.
        • Park B.
        • Chang S.H.
        • Lee K.S.
        • et al.
        Lung cancer risk and cigarette smoking, lung tuberculosis according to histologic type and gender in a population based case-control study.
        Lung Cancer. 2010; 68: 20-26
        • Sobue T.
        • Suzuki T.
        • Fujimoto I.
        • Matsuda M.
        • Doi O.
        • Mori T.
        • et al.
        Case-control study for lung cancer and cigarette smoking in Osaka, Japan: comparison with the results from Western Europe.
        Jpn J Cancer Res. 1994; 85: 464-473
        • Nakamura K.
        • Ukawa S.
        • Okada E.
        • Hirata M.
        • Nagai A.
        • Yamagata Z.
        • et al.
        Characteristics and prognosis of Japanese male and female lung cancer patients: the BioBank Japan project.
        J Epidemiol. 2017; 27: S49-S57
        • Mountain C.F.
        A new international staging system for lung cancer.
        Chest. 1986; 89: 225s-233s
        • Ichinose Y.
        • Yano T.
        • Asoh H.
        • Yokoyama H.
        • Yoshino I.
        • Katsuda Y.
        Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer: an analysis in each pathologic stage.
        J Thorac Cardiovasc Surg. 1995; 110: 601-605
        • Masuda R.
        • Kijima H.
        • Nito M.
        • Wada A.
        • Matsuzaki T.
        • Ikoma Y.
        • et al.
        Lymphatic invasion is a significant indicator of poor patient prognosis in lung squamous cell carcinoma.
        Mol Med Rep. 2017; 15: 2067-2073
        • Harpole Jr., D.H.
        • Herndon 2nd, J.E.
        • Young Jr., W.G.
        • Wolfe W.G.
        • Sabiston Jr., D.C.
        Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence.
        Cancer. 1995; 76: 787-796
        • Argon A.
        • Nart D.
        • Veral A.
        The value of cytokeratin 5/6, p63 and thyroid transcription factor-1 in adenocarcinoma, squamous cell carcinoma and non-small-cell lung cancer of the lung.
        Turkish J Pathol. 2015; 31: 81-88
        • Zhao W.
        • Wang H.
        • Peng Y.
        • Tian B.
        • Peng L.
        • Zhang D.C.
        ΔNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens.
        Int J Clin Exp Pathol. 2014; 7: 4247-4253
        • Gurda G.T.
        • Zhang L.
        • Wang Y.
        • Chen L.
        • Geddes S.
        • Cho W.C.
        • et al.
        Utility of five commonly used immunohistochemical markers TTF-1, Napsin A, CK7, CK5/6 and P63 in primary and metastatic adenocarcinoma and squamous cell carcinoma of the lung: a retrospective study of 246 fine needle aspiration cases.
        Clin Transl Med. 2015; 4: 16
        • Sturm N.
        • Lantuéjoul S.
        • Laverrière M.H.
        • Papotti M.
        • Brichon P.Y.
        • Brambilla C.
        • et al.
        Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung.
        Hum Pathol. 2001; 32: 918-925
        • Brambilla C.
        • Laffaire J.
        • Lantuejoul S.
        • Moro-Sibilot D.
        • Mignotte H.
        • Arbib F.
        • et al.
        Lung squamous cell carcinomas with basaloid histology represent a specific molecular entity.
        Clin Cancer Res. 2014; 20: 5777-5786
        • Moro D.
        • Brichon P.Y.
        • Brambilla E.
        • Veale D.
        • Labat F.
        • Brambilla C.
        Basaloid bronchial carcinoma. A histologic group with a poor prognosis.
        Cancer. 1994; 73: 2734-2739
        • Moro-Sibilot D.
        • Lantuejoul S.
        • Diab S.
        • Moulai N.
        • Aubert A.
        • Timsit J.F.
        • et al.
        Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis.
        Eur Respir J. 2008; 31: 854-859
        • Kim D.J.
        • Kim K.D.
        • Shin D.H.
        • Ro J.Y.
        • Chung K.Y.
        Basaloid carcinoma of the lung: a really dismal histologic variant?.
        Ann Thorac Surg. 2003; 76: 1833-1837
        • Shigematsu H.
        • Gazdar A.F.
        Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.
        Int J Cancer. 2006; 118: 257-262
        • Wong D.W.
        • Leung E.L.
        • So K.K.
        • Tam I.Y.
        • Sihoe A.D.
        • Cheng L.C.
        • et al.
        The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
        Cancer. 2009; 115: 1723-1733